Approximately 7 Percent of U.S. Population Uninsured in 2023
10.9 percent of adults aged 18 to 64 years were uninsured at the time of interview in 2023, as were 3.9 percent of children aged 0 to 17 years
Lebrikizumab Tied to Sustained Atopic Dermatitis Treatment Effect
Findings seen despite negligible remaining lebrikizumab serum concentrations following treatment withdrawal
Pandemic-Era Tax Credits Made Healthcare More Affordable, But They’re Set to Expire
No Evidence That Live Vaccines Are Unsafe for Patients on Dupilumab
Systematic review shows vaccine efficacy not affected by dupilumab in general
Health Care Spending Growth Projected to Outpace GDP to 2032
National health expenditures projected to have increased 7.5 percent in 2023, when COVID-19 public health emergency ended
Adverse Effects of Medical Treatment Increasing Worldwide
In high sociodemographic index region, age effects showed higher incidence rate in older adults
ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma
Neoadjuvant treatment followed by surgery results in longer event-free survival for resectable, macroscopic stage III melanoma
9.6 Percent of Medical Visits Took Place Via Telehealth in 2021
Percentage of telehealth visits was higher for mental health than other clinicians
1.5 Percent Ruxolitinib Cream Safe, Effective for Teens With Eczema
Ruxolitinib cream well tolerated, and disease control maintained over a year with as-needed use
Bimekizumab Yields Meaningful Response in Hidradenitis Suppurativa
Rapid clinically meaningful response seen, which was maintained for 48 weeks for moderate-to-severe hidradenitis suppurativa
